Crystalline forms of a phosphoinositide 3-kinase (PI3K) inhibitor

US11186580B2 · kind B2 · utility

Assignee

• Incyte Corporation · US

Inventors

• Brent Douty · Coatesville, US
• David M. Burns · Woodbury, US
• Andrew P. Combs · Kennett Square, US
• Zhongjiang Jia · Kennett Square, US
• Daniel Levy · San Mateo, US
• Eddy W. Yue · Landenberg, US

Key dates

• Filing date: Sep 4, 2019
• Grant date: Nov 30, 2021
• Expiry date: Dec 20, 2039

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07B2200/13
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to salts and crystalline forms of 2-(3-(8-Amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl)-4-methylphenyl)-3,3,3-trifluoro-2-hydroxypropanamide, crystalline forms of 8-amino-N-(2-hydroxy-2-methylpropyl)-3-(2-methyl-5-(1,1,1-trifluoro-2-hydroxypropan-2-yl)phenyl)imidazo[1,2-a]pyrazine-6-carboxamide, and crystalline forms of 8-amino-N-(2-hydroxy-2-methylpropyl)-3-(2-(methyl-d3)-5-(1,1,1-trifluoro-2-hydroxypropan-2-yl)phenyl)imidazo[1,2-a]pyrazine-6-carboxamide, which are PI3K inhibitors useful in the treatment of cancer and other diseases.